Search
Powered By HealthLine
Health Tools
 Heart Healthy Diet
 Ideal Body Weight Calculator
 Diet Reviews
 Fitness and Family
 Quiz: Test Your Fitness IQ
 Exercise and Fitness Guide
 Eat Out Smart
 Healthy Cooking
 BMI Calculator
Featured Conditions
 Diet & Exercise
 Stop Smoking
 Food & Fitness
 High Blood Pressure
 Cholesterol
 Heart
Resources
Healthscout News
3D Health Animations
Health Videos
Quizzes & Tools
Health Encyclopedia
Library & Communities
News Archive
Drug Library
Find a Therapist
Enter City or Zip Code:
Powered by Psychology Today



Channels
Home |  Today | Women| Men| Kids| Seniors| Diseases| Addictions| Sex & Relationships| Diet, Fitness, Looks| Alternative Medicine| Drug Checker
 Printer Friendly  Send to a Friend

ADHD Drugs Linked to Sudden Death in Kids

But these unexplained events are exceedingly rare, study finds

By Serena Gordon
HealthDay Reporter


Related Encyclopedia
 border=
Attention Deficit/Hyperactivity Disorder
Hypertension (High Blood Pressure)
More...

Related Animations
 border=
ADHD
Animation: What is Hypertension?
More...

Related Healthscout Videos
 border=
Stopping Stroke Damage: Time is Life!
Lyrics for Life: Hip Hop Artists' Lifesaving Move
Vision Revision for ADHD Diagnosis
Anaconda: Beating a Silent Killer
More...

Related News Articles
 border=
Best Friend Benefits Child's Mind, Body, Study Finds
Kindergartners Who Can Pay Attention May Reap Benefits Later
Chemo During Pregnancy Doesn't Seem to Harm Baby
When Mom Has Pregnancy Diabetes, Breast-Feeding Curbs Child Obesity
More...

MONDAY, June 15 (HealthDay News) -- Stimulant medications commonly prescribed to treat attention-deficit hyperactivity disorder (ADHD) are associated with an increased risk of sudden death, but those deaths are still rare, new research finds.

Children and teens taking ADHD stimulant medications were seven times more likely to die suddenly than their peers, the study found.

Text Continues Below



"What we found -- to our surprise -- is that even if you take out confounding factors, the association between stimulant use and sudden death was still significant," said study author Madelyn Gould, a professor of clinical epidemiology in psychiatry at Columbia University/New York State Psychiatric Institute in New York City. "I'm confident the association is real and significant, but it's very rare. I don't want our findings to change prescribing patterns or for a parent to change their willingness to use stimulant medications if they're called for, but physicians should monitor patients with any new medication you give a young person."

Results of the study were published in the June 15 online edition of the American Journal of Psychiatry.

As many as 2.5 million children in the United States take ADHD stimulant medications, such as amphetamine, dextroamphetamine (Adderall), methamphetamine or methylphenidate (Ritalin), according to an editorial in the same issue.

In the early 1990s, several reports of sudden, unexplained death in children taking these medications began to raise concerns. But the rarity of such deaths made them difficult to study. In 2006, the U.S. Food and Drug Administration requested that the prescribing information on these medications warn physicians against ordering the drugs for children with any known cardiac abnormalities. Current prescribing information also suggests that physicians request a thorough family history of heart problems and sudden deaths and perform a physical exam before starting youngsters on these medications.

Page:  1 | 2 | 3 | Next >>

Copyright © 2009 ScoutNews, LLC. All rights reserved.
Last updated 6/15/2009

Related Links
 border=
From Healthscout's partner site on diet & exercise, MyDietExercise.com
QUIZ: What's your ideal body weight?
QUIZ: Check your body mass index (BMI) online!
QUIZ: Rate your carbohydrate intake




SOURCES: Madelyn S. Gould, M.P.H., professor, clinical epidemiology in psychiatry, Columbia University/New York State Psychiatric Institute, New York City; Diego Chaves-Gnecco, M.D., developmental-behavioral pediatrician, Children's Hospital of Pittsburgh, Penn.; Benedetto Vitiello, M.D., psychiatrist and chief, child and adolescent treatment intervention branch, National Institute of Mental Health, Bethesda, Md.; American Journal of Psychiatry online, June 15, 2009; June 15, 2009 teleconference with Gerald Dal Pan, M.D., director, Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, and Robert Temple, M.D., director, Office of Drug Evaluation I, CDER, FDA


HealthScout is a part of HealthCentral
About Us   Our Blog   Contact Us   Privacy Policy   Terms of Use   Site Map  
Copyright © 2001-2012. The HealthCentralNetwork, Inc. All rights reserved.
Advertising Policy   Editorial Policy Advertise With Us   Anti-Spam Policy   PR Newswire